HHS Announces Department-Wide Clinical Trial Initiative - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

  • By

  • mdspire news news staff

  • June 23, 2026

  • 7 min

Share

Objective:

To strengthen the US position in clinical research and accelerate the development of new treatments, as announced by the US Department of Health and Human Services.

Approach:
    Key Findings:
    • China's share of global Phase 1 trials surpassed that of the US for the first time in 2021.
    • The average time for a US sponsor's IND submission is approximately 380 days.
    • Fewer than 5% of cancer patients receive treatment through clinical trials despite high willingness to participate.
    Interpretation:

    The initiative aims to address delays in clinical trial processes and enhance the US's competitive edge in clinical research.

    Limitations:
    • The roadmap does not provide specific timelines for implementation of proposed changes.
    • Potential challenges in aligning multiple HHS agencies and stakeholders.
    Conclusion:

    The initiative represents a comprehensive effort to modernize and expedite clinical trial processes in the US.

    Sources:

Original Source(s)

HHS Announces Department-Wide Clinical Trial Initiative

  • by mdspire news news staff

  • June 23, 2026

Related Content

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

Study uncovers factors potentially associated with lower LUTS risk

Sexual frequency was associated with lower odds of urinary symptoms in a US cohort but not a Chinese cohort.

High progesterone may be tied to syringoma

Elevated levels occurred in 29% of women with the condition compared with 6% of controls in a cross-sectional study.